Todd Berland, MD
Vascular Surgery · New York, NYNPI 1164406039
Payments from drug & device makers
Across 416 payments — averaging $787.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$160K
- Johnson & Johnson$56K
- Philips North America LLC$39K
- Medtronic$29K
- Cvrx, Inc.$16K
- Cook Research Incorporated$7K
- plus $21K from 27 others
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$2K
What the payments were for
- Consulting fees$116,87845%
- Speaking & faculty fees$119,29046%
- Travel & lodging$9,3784%
- Food & beverage$14,5626%
- Education$1120%
- Entertainment$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 77 | $159,700 |
| Johnson & Johnson | 67 | $55,501 |
| Philips North America LLC | 18 | $39,432 |
| Medtronic(2 entities) | 16 | $29,084 |
| Cvrx, Inc. | 12 | $16,395 |
| Cook Research Incorporated | 7 | $6,830 |
| Cardiovascular Systems Inc. | 43 | $4,916 |
| Boston Scientific | 39 | $4,856 |
| Reflow Medical Inc | 15 | $3,528 |
| Cook Medical LLC | 25 | $1,359 |
| Silk Road Medical, Inc. | 12 | $1,300 |
| Bolton Medical Inc | 11 | $752 |
| Bard Access Systems, Inc. | 6 | $740 |
| Laminate Medical Technologies Inc. | 3 | $550 |
| Endologix LLC | 7 | $449 |
| Inari Medical, Inc. | 8 | $381 |
| Tactile Systems Technology Inc | 7 | $314 |
| W. L. Gore & Associates, Inc. | 6 | $234 |
| Janssen Scientific Affairs, LLC | 2 | $230 |
| Humacyte Global, Inc. | 2 | $218 |
| Abbott | 8 | $202 |
| Imperative Care, Inc | 1 | $144 |
| Baxter Healthcare | 5 | $144 |
| Penumbra, Inc. | 4 | $125 |
| Pfizer | 4 | $86 |
| Cardiva Medical, Inc. | 3 | $66 |
| Terumo Medical Corporation | 2 | $60 |
| Truvic Medical, Inc. | 1 | $51 |
| Neuros Medical, Inc. | 1 | $28 |
| Smith+Nephew | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $17 |
| Venclose Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAVELINQ$71,762
- XARELTO$55,129
- Barostim Neo System$16,209
- (6554) Peripheral Vascular Undivided$6,428
- (9520) IGT Devices Undivided$5,189
- Peripheral Orbital Atherectomy System$3,738
- ENROUTE Transcarotid Neuroprotection System$1,021
- ENROUTE Transcarotid Stent System$1,021
- ENHANCE Transcarotid Peripheral Access Kit$1,021
- ENROUTE 0.014 Guidewire$1,021
- Lutonix Drug Coated Balloon$741
- VasQ External Support$459
- RotarexS 6 F x 135 cm$432
- Relay Plus$424
- Cook$379
- Zenith Spiral-Z$350
- Diamondback Peripheral$300
- FLEXITOUCH$249
- ACTITOUCH$249
- ENTRE$249
How this compares
$327,751 in reported general payments places this provider in the 95th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 121 | $71,580 |
| EliquisApixaban | 69 | $48,034 |
| ClopidogrelClopidogrel Bisulfate | 84 | $893 |
| Cilostazol | 26 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $55,501 | $71,580121 claims |
| PfizerEliquis | $86 | $48,03469 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in New York
- Gary GelbfishNew York$1.9M
- John LantisNew York$1.4M
- Brian DerubertisNew York$1M
- Thomas MaldonadoNew York$1M
- James McKinseyNew York$750K
- Peter FariesNew York$639K
- Virendra PatelNew York$590K
- Rami TadrosNew York$351K
- Ajit RaoNew York$329K
- Karan GargNew York$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.